XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Incentive Plans
 6 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Equity Incentive Plans Equity Incentive Plans

2013 Equity Incentive Plan

A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2020, 5,940,653 shares of common stock remained available for future grants under the 2013 Equity Plan.

2018 Employee Stock Purchase Plan

A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2020, 499,805 shares of common stock remained available for future grants under the ESPP.

Equity Awards

The activity related to equity awards, which are comprised of stock options and inducement grants, during the six months ended June 30, 2020 is summarized as follows:
 
Equity Awards
 
Weighted-
average
Exercise Price
per Share
 
Weighted-
average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2019
5,616,840

 
$
19.50

 
 
 
 
Granted
806,923

 
$
5.27

 
 
 
 
Exercised
(94,219
)
 
$
6.42

 
 
 
 
Cancelled/forfeited
(2,883,533
)
 
$
19.43

 
 
 
 
Outstanding at June 30, 2020
3,446,011

 
$
16.59

 
5.87 years
 
$
35,037

Exercisable at June 30, 2020
2,144,609

 
$
20.84

 
4.27 years
 
$
—



Share-based Compensation Expense

The classification of share-based compensation expense is summarized as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
Research and development
$
964

 
$
3,960

 
$
2,527

 
$
7,893

Selling, general and administrative
626

 
2,361

 
1,470

 
5,210

Total share-based compensation expense
$
1,590

 
$
6,321

 
$
3,997

 
$
13,103



As of June 30, 2020, total unrecognized share-based compensation expense related to unvested equity awards was $8.6 million, which is expected to be recognized over a weighted-average period of 2.2 years. As of June 30, 2020, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.